title: Histamine H2 receptor antagonist-refractory oesophagitis: the efficacy of long-term omeprazole maintenance treatment.
abstract: BACKGROUND
  Erosive oesophagitis refractory to high dose histamine H2 receptor antagonists (definition: failure to heal fully after > or = 3 months' treatment with cimetidine 3.2 g or ranitidine 0.9 g) responds well to omeprazole 40 mg daily but frequently relapses when the patients are put back on maintenance H2 receptor antagonists at medium or even high dose (e.g. cimetidine 1.6 g and 3.2 g, respectively).
  
  
  OBJECTIVE
  To investigate the efficacy of maintenance omeprazole 20 mg daily in refractory erosive oesophagitis.
  
  
  METHODS
  In this open, sequential study, patients with H2 receptor antagonist-refractory oesophagitis were healed on omeprazole 40 mg daily and then put on maintenance H2 receptor antagonists (cimetidine 1.6 g or 3.2 g). Relapses were re-treated with omeprazole 40 mg; upon rehealing, patients were put on maintenance omeprazole 20 mg daily for up to 4.5 years.
  
  
  RESULTS
  Healing on omeprazole occurred in 38 out of 39 patients (97%) at 12 weeks. Only six of the 38 patients (16%) relapsed (asymptomatic in half) during subsequent maintenance treatment, whereas all had relapsed earlier on high dose H2 receptor antagonists.
  
  
  CONCLUSIONS
  Within the limits of interpretation of an open study, omeprazole 20 mg daily seems effective in maintaining prolonged remission in this group of patients with H2 receptor antagonist-refractory oesophagitis.
authors.affiliation: Rotherham General Hospitals NHS Trust, United Kingdom.
authors.forename: K D
authors.initials: KD
authors.lastname: Bardhan
authors.forename: P
authors.initials: P
authors.lastname: Cherian
authors.forename: R B
authors.initials: RB
authors.lastname: Jones
authors.forename: A
authors.initials: A
authors.lastname: Vaishnavi
authors.forename: S
authors.initials: S
authors.lastname: Manek
authors.forename: A
authors.initials: A
authors.lastname: Bishop
authors.forename: J
authors.initials: J
authors.lastname: Polak
authors.forename: A
authors.initials: A
authors.lastname: Brooks
authors.forename: P
authors.initials: P
authors.lastname: Morris
authors.forename: M
authors.initials: M
authors.lastname: Thompson
authors.forename: J
authors.initials: J
authors.lastname: D'Silva
authors.forename: S
authors.initials: S
authors.lastname: Parkin
authors.forename: J
authors.initials: J
authors.lastname: Patterson
authors.forename: K R
authors.initials: KR
authors.lastname: Gillon
mesh_terms: D000328:Adult; D000368:Aged; D001706:Biopsy; D002927:Cimetidine / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D004351:Drug Resistance; D004791:Enzyme Inhibitors / Q000008:administration & dosage*; D004942:Esophagitis, Peptic / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D004947:Esophagus / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D005753:Gastric Mucosa / Q000187:drug effects; D005755:Gastrins / Q000032:analysis / Q000378:metabolism; D005773:Gastroscopy; D006635:Histamine H2 Antagonists / Q000008:administration & dosage*; D006801:Humans; D006965:Hyperplasia; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000008:administration & dosage*; D011899:Ranitidine / Q000008:administration & dosage*; D012008:Recurrence; D016896:Treatment Outcome; D014945:Wound Healing / Q000187:drug effects
chemical_list: D004791:Enzyme Inhibitors; D005755:Gastrins; D006635:Histamine H2 Antagonists; D002927:Cimetidine; D011899:Ranitidine; D009853:Omeprazole